-
1 Comment
FUREN Group Pharmaceutical Co., Ltd is currently in a long term uptrend where the price is trading 32.5% above its 200 day moving average.
From a valuation standpoint, the stock is 94.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.5.
FUREN Group Pharmaceutical Co., Ltd's total revenue sank by 34.9% to $693M since the same quarter in the previous year.
Its net income has dropped by 83.7% to $23M since the same quarter in the previous year.
Finally, its free cash flow grew by 104.0% to $710K since the same quarter in the previous year.
Based on the above factors, FUREN Group Pharmaceutical Co., Ltd gets an overall score of 3/5.
| CurrencyCode | CNY |
|---|---|
| Exchange | SHG |
| ISIN | CNE000000NM4 |
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Beta | 0.61 |
|---|---|
| Market Cap | 483M |
| PE Ratio | None |
| Target Price | None |
| Dividend Yield | 0.0% |
FUREN Group Pharmaceutical Co., Ltd. primarily engages in the manufacture and distribution of pharmaceuticals in Henan Province and Shanghai, China. The company produces traditional Chinese medicines, such as capsules, tablets, granules, injections, eye drops, oral liquids, cream, and others. The company was formerly known Shanghai Minfeng Industrial (Group) Co., Ltd. The company was founded in 1996 and is based in Henan, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 600781.SHG using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
